Clinical Trial Integrity and Risk Assessment for a Pharmaceutical Organization
HEALTHCARE · Compliance
We designed a compliance intelligence solution that ensured adherence to complex international regulations.
/ Project Information
Client
International Pharmaceutical Company
Industry
Healthcare / Life Sciences
Services
Due Diligence, Risk Intelligence, Background Investigations, Integrity Assessments, Strategic Advisory
Duration
12 Months
Region
Europe, North America, Asia-Pacific
A global pharmaceutical organization was preparing for a series of high-value clinical research programs involving multiple research institutions, contract research organizations (CROs), investigators and healthcare providers across several jurisdictions.
Given the substantial financial investment, regulatory obligations and reputational considerations associated with clinical trials, the organization sought to strengthen oversight throughout the research lifecycle. Senior leadership recognized that even isolated incidents involving data integrity concerns, undisclosed conflicts of interest, regulatory violations or unethical conduct could jeopardize years of scientific work and potentially expose the company to significant legal, financial and reputational consequences.
The company had traditionally relied on standard regulatory reviews and contractual safeguards when selecting research partners. However, the increasing complexity of international clinical research environments raised concerns regarding third-party integrity, governance standards, operational transparency and hidden risk factors that could remain undetected through conventional due diligence procedures.
Management required an independent intelligence-led assessment capable of providing deeper visibility into the organizations and individuals involved in critical research programs.
FOREUS established a specialized project team consisting of intelligence analysts, investigators, compliance specialists and life sciences advisors.
The engagement began with a comprehensive mapping of all entities involved in the planned research programs, including principal investigators, clinical trial sites, research institutions, service providers and external partners.
Our analysts conducted extensive due diligence and integrity assessments designed to identify indicators that could affect research quality, regulatory compliance or project continuity. Particular attention was given to governance structures, litigation history, regulatory findings, adverse media reporting, undisclosed affiliations and potential conflicts of interest.
In parallel, FOREUS developed a risk intelligence framework that allowed the organization to continuously evaluate emerging developments affecting key stakeholders throughout the duration of the clinical programs.
Rather than treating due diligence as a one-time exercise, the objective was to create ongoing visibility into potential risks capable of influencing research outcomes or organizational reputation.
FOREUS implemented a comprehensive clinical integrity and risk intelligence program that included:
- Enhanced due diligence investigations
- Research partner integrity assessments
- Background investigations
- Regulatory exposure reviews
- Litigation intelligence
- Adverse media monitoring
- Conflict-of-interest assessments
- Reputation risk analysis
- Third-party governance evaluations
- Continuous risk intelligence monitoring
The framework provided decision-makers with a structured understanding of risks associated with individual stakeholders and research partners before critical agreements were finalized.
Executive dashboards and periodic intelligence briefings enabled leadership teams to monitor changing risk conditions throughout the life of the research programs.
This intelligence-driven approach allowed the organization to supplement traditional compliance and regulatory reviews with a deeper understanding of integrity-related risks.
The project significantly strengthened the organization’s ability to identify and mitigate risks associated with complex international clinical research initiatives.
Several previously unknown concerns involving third-party entities were identified during the assessment process, allowing management to implement additional controls and, where necessary, reconsider engagement decisions before operational activities commenced.
The intelligence framework also improved transparency across the broader research ecosystem, providing leadership with greater confidence in partner selection, governance standards and program oversight.
As a result, the company reduced potential exposure to regulatory complications, reputational challenges and operational disruptions while strengthening overall trust in the integrity of its research programs.
Most importantly, the engagement enabled senior leadership to approach critical scientific investments with a higher degree of certainty and risk awareness.
Key Takeaway
In highly regulated industries such as life sciences and healthcare, success depends not only on scientific excellence but also on the integrity of the organizations and individuals involved. Intelligence-driven due diligence provides decision-makers with visibility beyond traditional compliance reviews, enabling them to identify hidden risks before they impact research outcomes, regulatory standing or corporate reputation.
FOREUS provided an additional layer of visibility that traditional due diligence simply could not achieve. Their intelligence-led assessments helped us make more informed decisions regarding research partners and strengthened confidence across our clinical programs.
Vice President, Clinical Operations
International Pharmaceutical Company (Europe)